<DOC>
	<DOCNO>NCT01806376</DOCNO>
	<brief_summary>1. purpose : explore maximum tolerate dose , dose-limiting toxicity oral Subutinib Maleate capsule rational dosage regimen phase Ⅱ study 2 . Experimental Design： A phase Ⅰ study single-center 3 . Test drug : Subutinib Maleate capsule 4 . Sample size≥20</brief_summary>
	<brief_title>A Phase I Study Subutinib Maleate Capsules Toleration Pharmacokinetics</brief_title>
	<detailed_description>The primary objective study explore maximum tolerated dose , dose-limiting toxicity oral Subutinib Maleate capsule rational dosage regimen phase Ⅱ study , investigate pharmacokinetics single multiple oral dos Subutinib Maleate capsule .</detailed_description>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Subjects histologically cytologically confirm solid tumor Subjects fail standard effective therapy diagnosis standard effective treatment available ; Aged 18 70 year old ; Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 ; Life expectancy great 3 month ; If subject give chemotherapy drug , 's necessary discontinue 4 week . If chemotherapy drug Nitrosoureas Mitomycin C , 's necessary discontinue 6 week . If subject accept major surgery , 's necessary wait 4 week subject participate study . Blood test : Hb≥100g/L ( blood transfusion within 14 day ) ; ANC≥1.5×109/L , PLT≥100×109/L Biochemistry : TBIL ALT AST Cr normal range , creatinine clearance ≥60ml/min ; Triglyceride≤3.0mmol/L ; Cholesterol ≤7.75mmol/L . Doppler ultrasound measurement : LVEF ≥ LLN Female subject agree take contraceptive study within 6 month study ( intrauterine device [ IUD ] , contraceptive drug condom ) ; within 7 day enter study , serum human chorionic gonadotropin negative , must nonlactation period ; male subject agree take contraceptive study within 6 month study . The subject willing participate study , he/she sign Informed Consent Form , good compliance . The subject participate drug clinical research past 4 week . The subject accompany several factor influence investigational drug administration orally , inability swallow gastrointestinal resection chronic diarrhea intestinal obstruction . Central nervous system metastasis definitely . The subject suffering hypertension myocardial ischemia myocardial infarction arrhythmia ( include QT interval≥440ms ) Grade I heart failure . If subject 's systolic BP 140mmhg , diastolic BP 90mmhg , subject 's blood pressure wellcontrolled , he/she permit enroll study well . The subject 's urinalysis display urinary protein ≥ ++ , combine 24hour urinary protein &gt; 1.0g . The subject 's suffering wound fracture cure long time . Abnormal coagulation : The subject bleeding tendency active peptic ulcer subject receive thrombolytic anticoagulant therapy . There predosing arterial/venous thrombotic event subject , cerebrovascular accident ( include TIA ) deep vein thrombosis pulmonary embolism . The subject accepting anticoagulant vitamin K antagonist warfarin heparin analogue therapy ; If subject 's INR ≤ 1.5 , he/she allow use small dos warfarin ( 1mg oral q ) small dos aspirin ( less 100mg day ) , purpose treatment prevention . Abnormal thyroid function . There history mental drug abuse occur subject , subject suffer mental disorder . There history immunodeficiency occur subject , include HIV positive acquire congenital immunodeficiency disease , subject accept organ transplant . Lung squamous cell carcinoma . The subject receive small molecule target drug therapy inhibition VEGFR2 PDGFRβ According investigator 's judgment , concomitant diseases seriously harm subject 's safety obstruct subject complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>